ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
METHOD
The use of wild-type blocking allele-specific real-time polymerase chain reaction for the analysis of somatic mutations in RAS genes of circulating free DNA isolated from the blood plasma of patients with colorectal cancer
About authors
Laboratory of Molecular Biology and Cytogenetics,Russian Research Center of Roentgenoradiology, Moscow, Russia
Correspondence should be addressed: Galina Snigireva
ul. Profsoyuznaya, d. 86, Moscow, Russia, 117997; ur.liam@lag_ins
About paper
Acknowledgements: the authors thank Andrey Zaretsky of Evrogen (Moscow) for his help and valuable advice in conducting molecular genetic analysis.
Contribution of the authors to this work: Telysheva EN — analysis of literature, research planning, data collection, analysis, and interpretation, drafting of a manuscript; Snigireva GP — research planning, data interpretation, drafting of a manuscript.
Received: 2017-08-08
Accepted: 2017-08-17
Published online: 2017-10-29
|
Table 1. Distribution of patients with colorectal cancer into groups depending on the levels of cell-free DNA circulating in their blood plasma before surgery and detection of cancer-associated mutations of the RAS genes by allele-specific real-time PCR
Note. Data are presented as median (Q1–Q3). Significance of difference was tested by comparing groups of patients with and without mutations in the RAS genes. * represents significant difference.
Table 2. Progression of colorectal cancer in patients characterized by cfDNA levels in their blood plasma measured prior to surgery and detection of cancer-associated mutations of the RAS genes by allele-specific real-time PCR
Note. Data are presented as median (Q1–Q3). Significance of difference was tested by comparing groups of patients with and without mutations in the RAS genes. * represents significant difference.
Table 3. Progression of colorectal cancer in patients characterized by cfDNA levels in their blood plasma measured after surgery and detection of cancer-associated mutations of the RAS genes by allele-specific real-time PCR
Note. Data are presented as median (Q1–Q3). Significance of difference was tested by comparing groups of patients with and without mutations in the RAS genes. * represents significant difference.
